Drugs / HZ-A-018
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04173455 | Oct 2019 → Sep 2021 | B-cell non-Hodgkin lymphoma | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HZ-A-018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04173455 ↗ |
| Action | Inhibit | “BTK) Inhibitor” NCT04173455 ↗ |
| Route | Oral | “orally administered HZ-A-018” NCT04173455 ↗ |
| Target | BTK | “Bruton Tyrosine Kinase (BTK) Inhibitor HZ-A-018” NCT04173455 ↗ |